Zobrazeno 1 - 10
of 47
pro vyhledávání: '"Yamin Shu"'
Publikováno v:
Frontiers in Pharmacology, Vol 15 (2024)
ObjectiveThis study aimed to explore the neurological adverse events of oxaliplatin through the Food and Drug Administration Adverse Event Reporting System (FAERS) database and to provide reference for safe clinical drug use.MethodsThe adverse events
Externí odkaz:
https://doaj.org/article/7721fa56f1ba4d3a8f98b53e6f691239
Publikováno v:
Heliyon, Vol 10, Iss 9, Pp e30437- (2024)
Background: Sotorasib has been approved for the treatment of adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC). Due to the limitations of clinical trials, potential adverse events (AEs) and long-t
Externí odkaz:
https://doaj.org/article/3edfe9dba4214ca4a317fda7e5ddeced
Publikováno v:
Pharmaceuticals, Vol 17, Iss 8, p 1028 (2024)
Background: Adalimumab has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of adult rheumatoid arthritis (RA), and subsequently approved for pediatric treatment of various autoimmune diseases in children of different ag
Externí odkaz:
https://doaj.org/article/ff9c0866ebed4adf8c8a75cc86b2a59c
Publikováno v:
BMC Cancer, Vol 23, Iss 1, Pp 1-13 (2023)
Abstract Background Rucaparib has been approved for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer. However, the long-term safety of rucaparib in large sample population was
Externí odkaz:
https://doaj.org/article/3bc485944c9442a5b5110520595877ef
Publikováno v:
BMC Nephrology, Vol 24, Iss 1, Pp 1-6 (2023)
Abstract Background Bevacizumab is a monoclonal antibody drug targeting Vascular Endothelial Growth Factor (VEGF), which binds to VEGF receptors to inhibit vascular endothelial cell proliferation and angiogenesis, thus inhibiting tumorigenesis. Pembr
Externí odkaz:
https://doaj.org/article/2e0395d0c66b40ee98734967ef62275b
Publikováno v:
Cancer Medicine, Vol 12, Iss 3, Pp 3365-3375 (2023)
Abstract Objective Poly ADP‐ribose polymerase inhibitors (PARPis) have significantly improved clinical effects in gynecological oncology. However, PARPis could also induce severe organ system toxicities, including the hematological system. Our stud
Externí odkaz:
https://doaj.org/article/348a71e64120456ab021f6e296829751
Publikováno v:
Scientific Reports, Vol 12, Iss 1, Pp 1-10 (2022)
Abstract Niraparib was approved for the treatment of platinum-sensitive recurrent epithelial ovarian cancer, fallopian tube and primary peritoneal cancer. The authors retrospectively investigated niraparib-related adverse events (AEs) through data mi
Externí odkaz:
https://doaj.org/article/1dee38b4f0ba4ead9d2c5d283c311156
Publikováno v:
Scientific Reports, Vol 12, Iss 1, Pp 1-11 (2022)
Abstract Osimertinib was a third-generation, irreversible epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), which approved by the US Food and Drug Administration (FDA) in 2015 for treatment of non-small cell lung cancer (NSCLC).
Externí odkaz:
https://doaj.org/article/031941a7dcc74c50bbf4a78aeb9db92c
Publikováno v:
Frontiers in Immunology, Vol 14 (2023)
BackgroundRisankizumab, a humanized IgG1 monoclonal antibody that selectively inhibits IL-23, is currently approved for the treatment of moderate-to-severe plaque psoriasis and Crohn’s disease. The real-world safety study of risankizumab in a large
Externí odkaz:
https://doaj.org/article/f9cac194dbd945198980edbaf75342a8
Publikováno v:
Frontiers in Immunology, Vol 14 (2023)
BackgroundSintilimab plus chemotherapy significantly prolongs overall survival (OS) for patients with advanced or metastatic oesophageal squamous cell carcinoma (OSCC). However, the cost-effectiveness of this high-priced therapy is currently unknown.
Externí odkaz:
https://doaj.org/article/67401d6092644ab096493080be2f5d52